Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genaera Corporation has begun a phase II clinical trial for its mucus regulating drug Lomucin in people with cystic fibrosis.
Subscribe to our email newsletter
Cystic Fibrosis Foundation Therapeutics, a nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, is supporting this trial with study-specific funding of up to $2.35 million dependent on achievement of milestones.
This study, which will be initiated in Ireland, will evaluate the use of Lomucin in two hundred individuals with cystic fibrosis (CF) through a multi-center, randomized, double-blind, placebo-controlled trial.
The study will assess the safety and efficacy of Lomucin oral tablets on pulmonary function and related symptoms. A previous exploratory phase II study demonstrated a trend toward better lung function in people with CF who took Lomucin compared to those receiving placebo tablets and found that Lomucin was well tolerated in the study.
“By evaluating a potential mucus-regulating drug, these researchers are pursuing a unique approach to CF therapy that could enhance the length and quality of life for those battling this disease,” said Dr Robert Beall, president and CEO of the Cystic Fibrosis Foundation.